



22 May 2024

Melissa Kostopoulos
ASX Compliance Pty Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

Dear Melissa

RESPONSE TO ASX PRICE QUERY

LTR Pharma Limited (ASX:LTP) ("LTR Pharma", "the Company"), refers to your letter dated 22 May 2024.

Using the numbering in your letter, we respond to your questions as follows:

1. No. The Company is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in the Company's securities.
2. On 25 March 2024, the Company reported that recruitment was successfully completed for its pivotal study of SPONTAN® Nasal Spray treatment of Erectile Dysfunction (ED), and all participants had received their final dosing as part of the study.

Furthermore, the Company reported on 29 April 2024 in its Quarterly Activities Report that the abovementioned study results were anticipated in mid-2024 and that this represents a critical milestone for the Company as it is designed to show that SPONTAN® could disrupt the global PDE5 (Viagra, etc) marketplace. The final data from the study is also expected to support the early access scheme in Australia and aid in pre-submission meetings with the FDA and TGA respectively.

The Company notes that the timing of the study data as noted above is coming closer to fruition.

The Company does not have any other explanation of the recent trading in its securities.

3. The Company confirms that it is in compliance with the Listing Rules and in particular, Listing Rule 3.1.
4. The Company confirms that the responses to the questions above have been authorised by the Board.

Authorised for release by the Board of Directors.



About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma's lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

For further information please contact:

Haley Chartres
Media Relations
haley@hck.digital

Jane Morgan
Investor Relations
jm@janemorganmanagement.com.au



22 May 2024

Reference: 94751

Ms Belinda Cleminson
Company Secretary
LTR Pharma Limited
9/204 Alice Street
Brisbane, QLD 4000

By email: belinda.cleminson@automicgroup.com.au

Dear Ms Cleminson

LTR Pharma Limited ('LTP'): Price - Query

ASX refers to the following:

A. The change in the price of LTP's securities from a low of \$0.34 on Monday 20 May 2024 to a high of \$0.50 today.

Request for information

In light of this, ASX asks LTP to respond separately to each of the following questions and requests for information:

1. Is LTP aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

If the answer to question 1 is "yes".

- (a) Is LTP relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in LTP's securities would suggest to ASX that such information may have ceased to be confidential and therefore LTP may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
2. If the answer to question 1 is "no", is there any other explanation that LTP may have for the recent trading in its securities?
 3. Please confirm that LTP is complying with the Listing Rules and, in particular, Listing Rule 3.1.
 4. Please confirm that LTP's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of LTP with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **3:30 PM AEST Wednesday, 22 May 2024**. You should note that if the information

requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, LTP's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require LTP to request a trading halt immediately.

Your response should be sent to me by e-mail at ListingsComplianceMelbourne@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in LTP's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in LTP's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to LTP's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that LTP's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Regards

ASX Compliance